367 related articles for article (PubMed ID: 30063012)
21. Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data.
Kim DY; Kim HJ; Han KH; Han SY; Heo J; Woo HY; Um SH; Kim YH; Kweon YO; Lim HY; Yoon JH; Lee WS; Lee BS; Lee HC; Ryoo BY; Yoon SK
Cancer Res Treat; 2016 Oct; 48(4):1243-1252. PubMed ID: 26910470
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.
McNamara MG; Slagter AE; Nuttall C; Frizziero M; Pihlak R; Lamarca A; Tariq N; Valle JW; Hubner RA; Knox JJ; Amir E
Eur J Cancer; 2018 Dec; 105():1-9. PubMed ID: 30384012
[TBL] [Abstract][Full Text] [Related]
23. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Johnson PJ; Qin S; Park JW; Poon RT; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Robles-Aviña J; Kudo M; Yan L; Sobhonslidsuk A; Komov D; Decaens T; Tak WY; Jeng LB; Liu D; Ezzeddine R; Walters I; Cheng AL
J Clin Oncol; 2013 Oct; 31(28):3517-24. PubMed ID: 23980084
[TBL] [Abstract][Full Text] [Related]
24. On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.
Howell J; Pinato DJ; Ramaswami R; Bettinger D; Arizumi T; Ferrari C; Yen C; Gibbin A; Burlone ME; Guaschino G; Sellers L; Black J; Pirisi M; Kudo M; Thimme R; Park JW; Sharma R
Aliment Pharmacol Ther; 2017 Apr; 45(8):1146-1155. PubMed ID: 28252185
[TBL] [Abstract][Full Text] [Related]
25. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
Lee JH; Chung YH; Kim JA; Shim JH; Lee D; Lee HC; Shin ES; Yoon JH; Kim BI; Bae SH; Koh KC; Park NH
Cancer; 2013 Jan; 119(1):136-42. PubMed ID: 22736425
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial.
Kim BK; Kim DY; Byun HK; Choi HJ; Beom SH; Lee HW; Kim SU; Park JY; Ahn SH; Seong J; Han KH
Int J Radiat Oncol Biol Phys; 2020 May; 107(1):106-115. PubMed ID: 32084526
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.
Nada Y; Rashad N; Eissa M; Ghonaim A; Farag K; Saadawi I; Sheha A; El Gewaity M; Abdel-Rahman O
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):99-107. PubMed ID: 29124987
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib in advanced hepatocellular carcinoma.
Llovet JM; Ricci S; Mazzaferro V; Hilgard P; Gane E; Blanc JF; de Oliveira AC; Santoro A; Raoul JL; Forner A; Schwartz M; Porta C; Zeuzem S; Bolondi L; Greten TF; Galle PR; Seitz JF; Borbath I; Häussinger D; Giannaris T; Shan M; Moscovici M; Voliotis D; Bruix J;
N Engl J Med; 2008 Jul; 359(4):378-90. PubMed ID: 18650514
[TBL] [Abstract][Full Text] [Related]
30. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
31. Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma.
Wang E; Xia D; Bai W; Yuan J; Li X; Niu J; Yin Z; Xia J; Cai H; Fan D; Han G; Liu L
BMC Cancer; 2019 Apr; 19(1):409. PubMed ID: 31039750
[TBL] [Abstract][Full Text] [Related]
32. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma.
Jeong SW; Jang JY; Lee JE; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim KH; Kim YJ
Asia Pac J Clin Oncol; 2012 Jun; 8(2):164-71. PubMed ID: 22524575
[TBL] [Abstract][Full Text] [Related]
34. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma.
Chen SW; Lin LC; Kuo YC; Liang JA; Kuo CC; Chiou JF
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1041-7. PubMed ID: 24661657
[TBL] [Abstract][Full Text] [Related]
35. Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma.
Labeur TA; Ten Cate DWG; Bart Takkenberg R; Azahaf H; van Oijen MGH; van Delden OM; de Man RA; van Vugt JLA; IJzermans JNM; Eskens FALM; Klümpen HJ
Acta Oncol; 2018 Nov; 57(11):1467-1474. PubMed ID: 29943624
[TBL] [Abstract][Full Text] [Related]
36. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib.
El Dika I; Capanu M; Chou JF; Harding JJ; Ly M; Hrabovsky AD; Do RKG; Shia J; Millang B; Ma J; O'Reilly EM; Abou-Alfa GK
Cancer Med; 2020 Oct; 9(20):7453-7459. PubMed ID: 32841541
[TBL] [Abstract][Full Text] [Related]
38. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
Xu L; Li P; Lin XJ; Yuan YF; Zhang YQ; Chen MS
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
[TBL] [Abstract][Full Text] [Related]
39. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
Kaneko S; Ikeda K; Matsuzaki Y; Furuse J; Minami H; Okayama Y; Sunaya T; Ito Y; Inuyama L; Okita K
J Gastroenterol; 2016 Oct; 51(10):1011-21. PubMed ID: 26931117
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
Rimassa L; Santoro A
Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]